PHA Medical Composition Adhesion Biocompatibility

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current hemostatic agents and medical adhesives lack sufficient adhesive strength for suturing and often induce immune responses, leading to poor biocompatibility.

Innovation Solution

A medical composition comprising polyhydroxyalkanoate (PHA) with a particle size of 10,000 nm or less, containing a repeat unit derived from 3-hydroxybutyrate (3HB) in amounts of 40% or more, and optionally including a repeat unit from 4-hydroxybutyrate (4HB), which exhibits high adhesive strength and biocompatibility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional hemostatic agents or medical adhesives are used, then bleeding prevention is achieved, but adhesive strength for suturing is insufficient and immune responses occur

Engineering Contradiction:
ImprovebiocompatibilityVSAvoidadhesive strength
Core Design Contradiction:
ReliabilityVSStrength

Solution Approach 1:

The patent changes the particle size parameter of PHA to 10,000 nm or less, which fundamentally alters the material's interaction with biological tissue. This parameter change enables both strong adhesion to moist tissues and reduced immune response, resolving the contradiction between adhesive strength and biocompatibility

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses copolymer PHA containing both 3HB units (providing structural integrity and adhesion) and 4HB units (improving biocompatibility and degradation). This composite polymer structure combines the benefits of both monomers to achieve both strong adhesion and low immunogenicity

Inventive Principle:
Principle #40Composite materials

2Strength

If PHA particle size is reduced to 10,000 nm or less, then adhesive strength and biocompatibility are improved, but manufacturing complexity increases

Engineering Contradiction:
Improvetissue adhesive strengthVSAvoidmanufacturing process complexity
Core Design Contradiction:
StrengthVSDevice complexity

Solution Approach 1:

The patent employs self-assembly mechanisms where PHA particles naturally form stable dispersions in aqueous solutions without requiring complex stabilization agents. The particles spontaneously organize and maintain their size distribution, simplifying the manufacturing process while achieving the desired particle size and performance

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The medical composition demonstrates excellent hemostatic efficacy, wound healing, tissue adhesion, bacterial infection inhibition, and antibacterial properties, with strong adhesive strength even on moist biological tissues.

Implementation Method 1

the medical composition may have a tissue adhesive strength of 15 kPa or more when measured at a relative humidity of 100% and room temperature

Methodology Applied
Scientific EffectAdhesion: Adhesive

Data Source

PatentEP4548938A1Medical composition
Publication Date: 2025.05.07 CJ CHEILJEDANG CORP
  • EP4548938A1 patent drawingFigure 1
  • EP4548938A1 patent drawingFigure 2
  • EP4548938A1 patent drawingFigure 3~4

AI summary

The present disclosure relates to a medical composition containing polyhydroxyalkanoate (PHA). The medical composition can exhibit excellent biodegradability, biocompatibility, adhesion to biological tissues, wound healing efficacy, and hemostatic efficacy. Therefore, the medical composition according to the present disclosure can be used for hemostasis, wound healing, tissue adhesion, or inhibition of bacterial infection.